Market revenue in 2023 | USD 1.8 million |
Market revenue in 2030 | USD 2.9 million |
Growth rate | 7.2% (CAGR from 2023 to 2030) |
Largest segment | Mrna reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 33.33% in 2023. Horizon Databook has segmented the Norway cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
Growing research on cell reprogramming is anticipated to boost the market in Norway. The presence of Norwegian Center for Stem Cell Research in the country, with a specific focus on advancing in vitro models based on iPS cells for endocrine, neurological, and ocular diseases, is one of the factors driving the Norway cell reprogramming market.
Comprising 10 research groups, the center excels in differentiating hiPS cells into ocular, neural, and endocrine cell types, employing diverse methodologies, such as 2D and 3D culture systems, directed cell differentiation, organoid generation, microfluidics, gene expression assays, electrophysiology, CRISPR-based gene editing, and high-throughput functional imaging.
Moreover, the center operates the National Core Facility for hiPS cells and offers charged services for characterizing, reprogramming, & banking research-grade iPS cells, provides instruction in iPS cell-related techniques, and facilitates the use of advanced cell culture facilities & instruments.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into Norway cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account